Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NRIX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Bexobrutideg (NX-5948) | B-cell Lymphoma | Phase 3 · NCT07516093 | Recruiting |
| Drug Product De-TIL-0255 | Platinum-resistant Ovarian Cancer | Phase 1 · NCT05107739 | Terminated |
| Esomeprazole | Healthy Volunteer | Phase 1 · NCT06717269 | Completed |
| CBL-B Inhibitor NX-1607 | Ovarian Cancer, Epithelial | Phase 1 · NCT05107674 | Recruiting |
| Zelebrudomide (NX-2127) | Chronic Lymphocytic Leukemia (CLL) | Phase 1 · NCT04830137 | Recruiting |
| Quinidine | Healthy Volunteer | Phase 1 · NCT06717269 | Completed |
| Rosuvastatin | Healthy Volunteer | Phase 1 · NCT06717269 | Completed |
Also used in these trials (approved or third-party drugs, not NRIX's own candidates): Pirtobrutinib, Obinutuzumab, Rituximab, Venetoclax, Digoxin, Famotidine, Midazolam Hydrochloride, Paclitaxel.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NRIX holds $1.1B in cash and short-term investments (as of Aug 31, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 14 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NRIX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 7,527,996 | 6.89% | 2025-12-31 |
| Vestal Point Capital, LP | Institution (13G, 5%+) | 7,025,000 | 6.43% | 2026-09-30 |
| Deep Track Capital, LP | Institution (13G, 5%+) | 6,000,000 | 5.49% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 5,202,025 | 4.76% | 2026-06-30 |
| Gwenn Hansen Chief Scientific Officer · +187,434 options |
Insider | 123,452 | 0.11% | 2026-10-30 |
| Houte Hans van Chief Financial Officer · +129,480 options |
Insider | 42,745 | 0.04% | 2026-11-04 |
| Julia P Gregory Director · +31,250 options |
Insider | 10,750 | 0.01% | 2026-10-14 |
| Christine Ring Chief Legal Officer · +234,945 options |
Insider | 4,406 | 0.00% | 2026-11-02 |
Share count 109,249,814 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NRIX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →